Objective: To systematically determine the imaging findings for distinguishing malignant and benign branch-duct type intraductal papillary mucinous neoplasms (BD-IPMNs), including mixed type, and their diagnostic value through meta-analysis of published studies. Background: Management of BD-IPMNs, including mixed type, largely relies on imaging findings. The current knowledge on imaging findings to distinguish malignant and benign BD-IPMNs has weak evidence and is mostly from scattered individual retrospective studies. Methods: Thorough literature search in Ovid-MEDLINE and EMBASE databases was conducted to identify studies where findings of computed tomography, magnetic resonance imaging, and endoscopic ultrasonography of BD-IPMNs with or without main pancreatic duct (MPD) dilatation were correlated with surgical/pathological findings. Review of 1128 article candidates, including full-text review of 102 articles, identified 23 eligible articles with a total of 1373 patients for meta-analysis. Dichotomous data regarding distinction between malignant and benign BD-IPMNs were pooled using random effects model to obtain the diagnostic odds ratios (DORs) and their 95% confidence intervals (CIs) of various individual imaging findings for diagnosing malignant BD-IPMN. Results: Presence of mural nodules revealed the highest pooled DOR (95% CI) of 6.0 (4.1-8.8) followed by MPD dilatation [3.4 (2.3-5.2)], thick septum/wall [unadjusted, 3.3 (1.5-6.9); publication bias-adjusted, 2.3 (0.9-5.5)], and cyst size greater than 3 cm [2.3 (1.5-3.5)]. Multilocularity and multiplicity of the cystic lesions did not reveal statistically significant association with malignancy. Conclusions: Presence of mural nodules should be regarded highly suspicious for malignancy warranting a surgical excision whereas cyst size greater than 3 cm, MPD dilatation (5-9 mm), or thick septum/wall may better be managed by careful observation and/or further evaluation.
O ne of the most controversial issues regarding the management of branch-duct type intraductal papillary mucinous neoplasms (BD-IPMNs) of the pancreas without or with (ie, including mixed type) associated main pancreatic duct (MPD) dilatation is the management decision between operation and watchful observation. 1 Surgical resection provides the best chance for cure for patients who have malignant BD-IPMNs; however, watchful observation would be a better option for the patients who have low risk of malignancy given the morbidity and risks related to the pancreatic surgery. Hence, it is important to identify factors to suggest the lesions that have a high risk of malignancy.
In practice, such management decision largely relies on imaging examinations and demonstration of imaging features indicative of malignancy. However, some ambiguity exists regarding how to interpret and synthesize the imaging features to determine the management for BD-IPMN patients. To help guide such management decision, international consensus guidelines for the management of IPMNs and mucinous cystic neoplasms were proposed in 2006 (the 2006 guidelines). 2 According to the 2006 guidelines, resection of a BD-IPMN, including mixed-type, is recommended if one or more of the following features are present: cyst size greater than 3 cm, MPD diameter greater than 6 mm, presence of mural nodules, and presence of symptoms. However, since the 2006 guidelines, it appears that the management of BD-IPMNs has been gradually gravitating toward more deliberate observation rather than surgical resection, 3 rendering the role of imaging in identifying those who do not need an immediate surgery more important. In particular, the value of cyst size greater than 3 cm as a predictor for malignancy and a surgical indication has been questioned by new studies suggesting otherwise. 1, 4 As a result, the international consensus guidelines were revised in 2012 (the 2012 guidelines), in which the analysis of imaging findings has been further emphasized and has become more sophisticated compared with the 2006 guidelines, including categorization of imaging findings into "high-risk stigmata" to recommend surgical resection without further testing and "worrisome features" to require further evaluation with endoscopic ultrasonography (EUS) and/or cytology. 3 There have been multiple scattered individual studies to determine the imaging findings to suggest malignant BD-IPMNs; however, the vast majority of them were retrospective studies with low-level evidence. 5, 6 The 2006 and 2012 guidelines may represent a summary of the past study results; however, the consensus guidelines are still an intuitive qualitative abstract of the past study results combined with empirical expert opinions. To our knowledge, no attempt has yet been made to generate a more evidence-based systematic summary about the imaging findings suggestive of malignant BD-IPMNs, which would be of great impact and help for a more evidencebased standardized management of patients who have BD-IPMNs. To this end, we performed this systematic review and meta-analysis to determine the imaging findings for distinguishing malignant and benign BD-IPMNs, including mixed type, and their diagnostic value.
METHODS

Literature Search Strategy
A computerized search of Ovid-MEDLINE and EMBASE databases was conducted to find relevant original publications on prediction of malignancy for BD-IPMN or accuracy of diagnosing malignant BD-IPMN. The following search terms were used: (pancrea * and "intraductal papillary mucinous") and (computed tomography or CT or magnetic resonance imaging or MRI or magnetic resonance cholangiopancreatography or MRCP or magnetic resonance pancreatography or MRP or endoscopic ultraso * or endoscopic sonography or endosonography or EUS or positron emission tomography or PET or imaging or predictor or predict * ). "Positron emission tomography or PET" was included in the search query as studies on positron emission tomography (PET) might contain data on computed tomography (CT), magnetic resonance imaging (MRI), or EUS although PET itself generally cannot assess the detailed morphological features of BD-IPMNs. "Predictor or predict * " was included so as not to neglect any studies which were actually on imaging predictors for malignant IPMNs but happened not to contain the names of the imaging examinations in the title or abstract. No beginning date limit was used and, to make the data sources as current as possible, we continued updating the literature search until December 8, 2012. Our search was restricted to human subjects and English-language studies. To expand the search, the bibliographies of articles that remained after the selection process were screened for other potentially suitable articles. For management of literatures, Endnote version X5 (Thomson Reuters, New York, NY) was used.
Terminology and Histological Criteria
In our study, the terminology BD-IPMN implies IPMN with cystic lesions originating from the branch ducts either without (ie, pure type) or with (ie, mixed type) MPD dilatation. This definition follows the view which considers MPD dilatation as an indicator of malignancy in the presence of BD-IPMN rather than as a condition to reclassify the lesion into a new category, that is, mixed type, and is consistent with the 2012 guidelines for the management of IPMNs. 3 Therefore, we included studies addressing pure BD-IPMNs as well as studies presenting aggregate data for both pure and mixed BD-IPMNs. The distinction between mixed BD-IPMN and main-duct IPMN followed the lesion definitions adopted by the individual original studies and the vast majority of related studies in the literature search categorized any IPMNs accompanied by MPD diameter greater than 10 mm as main-duct type IPMNs. Regarding the histological definition of a malignant IPMN, slightly different definitions have been used in different reports. The criteria of malignancy used in this study was according to the 2000 World Health Organization classification, which categorizes IPMNs into adenomas, borderline lesions (moderate dysplasia), noninvasive carcinomas (high-grade dysplasia or carcinoma in situ), and invasive carcinomas and considers the noninvasive carcinomas and invasive carcinomas as malignant IPMNs.
Inclusion Criteria
Studies or subsets in studies investigating the imaging predictor for or diagnosis of malignant IPMN in patients with BD-IPMNs were eligible for inclusion. Studies or subsets of studies that satisfied all of the following criteria were included: 
Exclusion Criteria
The exclusion criteria were as follows: (a) case reports and case series with the sample size smaller than 8 patients or studies with potential selection bias (ie, nonconsecutive series of patients); (b) review articles, editorials, letters, comments, and conference proceedings; (c) studies that used clinical follow-up as the reference standard without pathological confirmation; (d) studies not within the field of interest of this study; (e) studies with insufficient data to reconstruct the diagnostic 2-by-2 table; and (f) studies, the relevant data of which overlapped with other studies due to patient overlap. Two reviewers (K.W.K. and S.H.Y.) independently selected literatures using a standardized protocol. Disagreements were resolved by consensus with a third reviewer (J.P.).
Data Extraction
From the selected studies, we extracted the following data onto standardized data forms: (a) study characteristics such as authors, year of publication, hospital or medical school, years of patient recruitment, sample size, study design, and criteria for malignancy; (b) demographic characteristics: mean age, sex, and proportion of malignant BD-IPMNs; (c) imaging characteristics: size of the pancreatic cystic lesions, mural nodules in the cystic lesions, MPD dilatation, multiplicity and multilocularity of the cystic lesions, and presence of thick septum/wall; and (d) outcomes: number of true positives, false positives, false negatives, and true negatives of imaging findings for diagnosing malignant BD-IPMNs. As MPD dilatation was not defined the same way across the studies, the overall presence of MPD dilatation (ie, all reports of MPD dilatation without regard to the specific ductal diameter thresholds) and the threshold MPD diameter to define the dilatation were recorded. One reviewer (K.W.K.) extracted data from the studies and the second reviewer (S.H.Y.) double-checked the accuracy of extracted data.
Quality Assessment
The methodological quality of the included studies was assessed by using Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) criteria by consensus between 2 reviewers (K.W.K. and J.P.). 8 in addition to the primary analysis for the overall MPD dilatation. The meta-analytic pooling was based on the inverse variance method for calculating weights; and the pooled DOR and its 95% confidence interval (CI) were obtained using the DerSimonian-Liard random effects model. Heterogeneity of the pooled data was assessed by using Cochran Q method and quantified with the I 2 statistics. 9 An I 2 value greater than 50% was considered to indicate substantial heterogeneity. Publication/reporting bias was visually assessed using the funnel plot, and the statistical significance was tested using the Begg test and the Egger test. 10 Publication bias-adjusted pooled estimates, that is, adjusted DORs, were also obtained using the trim-and-fill method. 11 If the original unadjusted DOR and the trim-and-fill adjusted DOR agreed, the results were regarded to be robust to publication bias. We also obtained the summary receiver operating characteristics curve and the area under the curve (AUC) as an additional global measure of test accuracy. 12 The pooled sensitivity, specificity, and positive and negative likelihood ratios (LRs) of imaging findings were assessed by a bivariate random-effects approach. 13 For the statistical analysis, Meta-Disc version 1.4 (Meta-Disc, Unit of Clinical Biostatistics team of the Romany Cajal Hospital, Madrid, Spain) and Stata version 10 (StataCorp LP, College Station, Texas) were used.
RESULTS
Literature Search
Our study selection process is described in Figure 1 . The literature search in Ovid-MEDLINE and EMBASE databases generated 1694 initial article candidates and 1128 articles were screened for eligibility after removing duplicates. Of those, 1026 articles were excluded after the review of the titles and the abstracts: 196 review articles; 237 case reports or series containing less than 8 relevant patients; 193 letters, editorials, or conference abstracts; and 400 articles that were not in the field of interest of this study. The full texts of the remaining 102 articles were retrieved. The search of the bibliographies of these articles found no additional eligible studies. Of the 102 articles, the following 79 articles were further excluded after reviewing the full texts: 5 studies without analysis of imaging parameters; 6 studies lacking histological confirmation of the lesions to serve as the reference standard; 9 studies that used ineligible criteria for malignant BD-IPMN including 5 studies categorizing borderline histology as malignant IPMN [14] [15] [16] [17] [18] and 4 studies considering only invasive carcinomas as malignant IPMN; [19] [20] [21] [22] 9 studies that were not in the field of interest; 19 studies presenting insufficient data for construction of the diagnostic 2-by-2 table for BD-IPMNs; 22 studies that did not separate the data for main-duct IPMNs and the data for BD-IPMNs; and 9 studies that had relevant data/patients overlapped with other studies. [23] [24] [25] [26] [27] [28] [29] [30] [31] Finally, 23 eligible studies with the total sample size of 1373 patients who had BD-IPMNs were included in this meta-analysis. 
Characteristics of Included Studies
The detailed characteristics of the finally included 23 studies are summarized in Table 1 . There was patient overlap between Jang et al's report 39 and Hwang et al's report, 38 and between Salvia et al's report 49 and Rodriguez et al's report; 48 however, these studies were not excluded as each pair of studies had no overlap between the 2 studies in the data to be extracted, that is, data only on the size and multilocularity of BD-IPMNs from Jang et al's article 39 but other lesion characteristics from the other study and, similarly, only the size and presence of thick septum/wall from Salvia et al's article 49 but other lesion characteristics from the other study. Twenty-one studies were retrospective studies, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [50] [51] [52] [53] [54] whereas 2 studies used prospective registries. 48, 49 The quality of included studies as assessed by the QUADAS-2 tool was overall good, with all studies satisfying 5 or more of the total 7 items. 8 Blinding of the imaging analysis to the reference standards (QUADAS-2 Domain 3) was not done or was not clearly stated in many studies, likely related to the retrospective nature of the studies. 32, 34, [37] [38] [39] 43, 44, 46, 47, 51, 52, 54 Fourteen studies used multiple imaging modalities, including CT, EUS, or MRI to evaluate the lesion characteristics, 32, 34, [37] [38] [39] 43, 44, [46] [47] [48] [50] [51] [52] 54 whereas 9 studies used 1 specific imaging method including CT (n = 6), 33, 35, 36, 42, 45, 53 EUS (n = 2), 39, 40 and MRI (n = 1). 49 Considering the heterogeneity in the use of the imaging modalities, random-effects models were applied to obtain more accurate meta-analytic pooled estimates.
In terms of the demographic characteristics of the included studies, the mean ages were from 60 to 69 years (median 64.9 years) and the male-to-female ratios were 0.7 to 4.4 (median 1.5). The proportions of malignant lesions were 12% to 62% for all BD-IPMNs [median, 28%; pooled proportion based on random effects model, 31% (95% CI, 24%-38%)] and 12% to 41% for pure BD-IPMNs [median, 22%; pooled proportion, 21% (95% CI, 17%-26%)] ( Figure 2 ).
Imaging Diagnosis of Malignant BD-IPMN
The pooled DORs of various imaging findings for the diagnosis of malignant BD-IPMNs are summarized in Table 2 . The pooled DOR was the highest for the presence of mural nodules (DOR, 6.0; 95% CI, 4.1-8.8) followed by MPD dilatation (DOR, 3.4; 95% CI, 2.3-5.2), thick septum/walls (DOR, 3.3; 95% CI, 1.5-6.9), and size of cyst greater than 3 cm (DOR, 2.3; 95% CI, 1.5-3.5). The corresponding forest plots are shown in Figure 3 . When different cut-off values for the cyst size and the specific thresholds for MPD diameter were used to distinguish malignant and benign BD-IPMNs, cyst size greater than 4 cm or 2 cm and MPD diameter greater than 7 mm did not reach statistical significance, demonstrating the 95% CIs of their pooled DORs enclosing 1.0. Multilocularity and multiplicity of the cystic lesions did not reveal statistical significance, either. No substantial heterogeneity was found in analyzing the pooled data except for the MPD diameter threshold of 7 mm (I 2 = 62.8%).
No significant publication/reporting bias existed for cyst size greater than 3 cm, presence of mural nodule, and MPD dilatation as bias (ie, possible missing data) using the trim-and-fill approach, the adjusted pooled DORs for cyst size greater than 3 cm, presence of mural nodules, and MPD dilatation were still similar to those unadjusted values and retained statistical significance as expected, indicating that the results were robust to bias (Table 2 ). However, the trim-and-fill adjusted DOR for thick septum/wall did not reach a statistical significance with the lower margin of the 95% CI falling slightly below 1.0 ( Table 2) . The pooled sensitivity and specificity for diagnosing malignant BD-IPMNs of those imaging findings, which revealed statistically significant DOR (including thick septum/wall), are shown in Table 3 . Of those, presence of mural nodule showed the highest AUC of 0.787 and the highest pooled specificity of 83% (95% CI, 80-85) but low corresponding pooled sensitivity of 59% (95% CI, 53-64). Positive and negative LRs of the imaging findings ranged from 1.5 to 2.9 and 0.6 to 0.7, respectively.
DISCUSSION
This meta-analysis investigated the imaging findings for differentiating malignant BD-IPMNs from benign BD-IPMNs and the diagnostic value of the imaging findings. The presence of mural nodules was the most suggestive imaging finding for malignant BD-IPMNs, followed by MPD dilatation, thick septum or cyst wall (despite some uncertainly related to the publication bias), and size of cyst greater than 3 cm. Our meta-analysis result is generally in agreement with the 2012 international consensus guidelines, which give different weights to the suspicious imaging findings by categorizing them into "high-risk stigmata" (which requires immediate surgical resection) and "worrisome features" (where further evaluation is recommended). 3 However, at the same time, the overall small positive and large negative LRs of these findings (1.5-2.9 and 0.6-0.7, respectively) for diagnosing malignant BD-IPMNs may also reveal the intrinsic limitation of these imaging parameters as a predictor for malignant BD-IPMN because an impeccable test to diagnose a malignancy generally requires positive LR greater than 5.0 and negative LR smaller than 0.1 to rule in and rule out, respectively, the disease. 55 The lack of descriptions about the enhancement of the mural nodules after intravenous contrast administration in the included studies made it impossible to reconfirm the nature of each mural nodule as a true neoplastic growth. Given the possibility of some nonneoplastic intracystic debris presenting as mural nodules in the pooled data, the diagnostic value of mural nodule as an indicator of malignancy might have been even greater if true enhancing mural nodules are considered separately. Nevertheless, our study demonstrates that the presence of mural nodule by itself, regardless of its enhancement, increases the odds of malignancy approximately by 6 folds (ie, unadjusted and the publication bias-adjusted DOR of 6.0 and 5.5, respectively). In addition, the presence of mural nodule showed the highest (and fairly higher than others) pooled AUC and specificity (0.787 and 83%, respectively). From these results, we believe that it may be acceptable to consider the presence of mural nodule as a highly suspicious finding for malignancy to recommend a surgical resection. Given the low sensitivity of the finding (the pooled sensitivity of 59%), however, an absence of mural nodules alone should not preclude surgical management. 1 Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
The 2012 guidelines 3 also consider MPD diameter greater than 10 mm as another high-risk stigmata to suggest a surgery. However, this could not be verified in our meta-analysis because there was only a single study 41 in our literature search outcome, which contained additional specific data on the diagnostic value of MPD diameter threshold of 10 mm besides other data pertinent to this meta-analysis. In fact, as mentioned previously, the vast majority of related studies categorized any IPMNs accompanied by MPD diameter greater than 10 mm as main-duct type IPMNs.
Although cyst size greater than 3 cm, MPD dilatation, and thick septum/wall showed statistically significant association with malignant BD-IPMN, their absolute diagnostic value as an indicator of malignancy was fairly weak (pooled specificity of 60%-67%). From these results, it would be reasonable to consider them as worrisome features and patients who have these findings alone may well be managed by careful follow-up. BD-IPMN with cyst greater than 3 cm has traditionally been considered an indication for surgical resection, for example, as shown in the 2006 guidelines. 2 However, recently, it has become a controversial issue as reports of large case series demonstrating no significant difference in the rate of malignancy between cysts greater than 3 cm and smaller lesions have been appearing: Hirono el al 37 [17/83] , P = 1.00). Our meta-analysis may help clarify on this issue and suggests that a BD-IPMN merely measuring greater than 3 cm without other indications of malignancy may not justify an immediate surgical resection. Regarding the cut-off MPD diameter to separate worrisome and not worrisome lesions in practice, the 5-mm threshold is currently adopted by the 2012 guidelines 3 ; and our subgroup analysis results demonstrating a DOR of 4.4 (95% CI, 2.4-8.1) for the 5-mm threshold may provide the quantitative evidence for the appropriateness of the current guideline.
The strengths of our study include the use of exhaustive literature search and validated systematic review methods and the reporting of the study results according to the standard reporting guidelines, Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). 56 In addition, robust statistical procedures were used to estimate the presence of reporting bias, and we employed the trim-and-fill method to adjust the bias.
Our study had several limitations. First, unlike the usual metaanalysis of diagnostic studies, we intended to obtain the meta-analytic summary on the diagnostic value of individual imaging findings instead of assessing the overall diagnostic accuracy of any particular imaging modality because the former information was more relevant to and directly helpful in making an image-guided management decision for BD-IPMNs. Also, the number of studies evaluating the overall accuracy of CT, MRI, or EUS for diagnosing malignant BD-IPMNs was surprisingly small. As we focused on the individual imaging findings without regard to the imaging modalities used to obtain the imaging findings, the heterogeneity of the included imaging tests could be an issue. However, we tried to minimize this factor by adopting random-effects models for the statistical analysis. Second, the rapid developments in medical imaging technologies may have caused temporal heterogeneity of the included studies, which may have introduced some inconsistency in the results. Third, as our study mandated pathological correlation using surgically resected specimen as the reference standard, the study inevitably ended up excluding those BD-IPMNs that were observed or were managed conservatively without surgery for various reasons. The effect of such exclusion on the study results is rather ambiguous. Finally, although we considered both noninvasive carcinomas (ie, high-grade dysplasia or carcinoma in situ) and invasive carcinomas as malignant lesions according to the 2000 World Health Organization classification of IPMNs, given the different tumor behavior between the 2 categories and the fact that the diagnosis of invasive cancers is often straightforward at imaging, a separate analysis for the diagnosis of noninvasive carcinomas would have been informative. However, unfortunately, such analysis was not feasible as most studies identified did not contain any pertinent data.
CONCLUSIONS
The presence of mural nodules in a BD-IPMN at imaging should be regarded highly suspicious for malignancy warranting a surgical excision, whereas cyst size greater than 3 cm (a traditional indication for surgery), MPD dilatation (5-9 mm), or thick septum/wall without other indications of malignancy may better be managed by careful observation and/or further evaluation.
